Eikon pulls in $351M as lead drug begins Phase III journey

Eikon Therapeutics Secures $351M Funding for Cancer Drug Development Eikon Therapeutics raised $351 million in a Series D funding round124 Total funding raised since 2019 launch now exceeds $1.1 billion1 Lead drug EIK1001 has entered Phase III trials for advanced melanoma14 Clinical studies ongoing in 28 countries across 5 continents14 ## Pipeline Highlights: EIK1001: TLR7/8 […]